Search results
Greenwood Capital Associates LLC Buys 65 Shares of Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 14 hours agoGreenwood Capital Associates LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 0.3% in the 4th quarter, Holdings Channel reports. The fund owned ...
Biogen Inc. (NASDAQ:BIIB) Receives $286.50 Consensus Target Price from Analysts
ETF DAILY NEWS· 3 days agoShares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-six brokerages that are covering the ...
Cim Investment Management Inc. Trims Position in Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 4 days agoCim Investment Management Inc. decreased its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 4.2% in the fourth quarter, according to its most recent Form 13F filing ...
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Zacks via Yahoo Finance· 3 days agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
...NOTICE: If You Suffered Losses on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to...
Morningstar· 6 days agoNEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities ...
Connectus Wealth LLC Has $469,000 Position in Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 6 days agoConnectus Wealth LLC reduced its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 14.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,814 ...
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
Morningstar· 6 days agoLOS ANGELES, June 11, 2024 /PRNewswire/ -- , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ ...
FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
Barrons.com· 6 days ago“Leqembi has had a lackluster launch thus far due to various administrative challenges and hurdles,”...
Two Is Better Than One in the Alzheimer’s Market
The Wall Street Journal· 11 hours agoThe approval of Eli Lilly’s Alzheimer’s drug donanemab could help build momentum for Biogen’s struggling drug Leqembi.
Eli Lilly Pushes Alzheimer's Stocks Lower On FDA Win
Investor's Business Daily· 6 days agoDespite the stock move, analysts largely expect donanemab to gain FDA approval. Late Monday, the advisors to the FDA voted unanimously that the clinical...